Background. The development of de novo donor-specific antibodies (dnDSA) has been associated with rejection and graft loss in kidney transplantation, and DSA screening is now recommended in all kidney transplant recipients. However, the clinical significance of dnDSA detected by screening patients with a stable creatinine remains unclear. Methods. One hundred three patients younger than 18 years receiving a first, kidney alone transplant between December 1, 2007, and December 31, 2013, underwent DSA screening every 3 months for 2 years posttransplant, with additional testing as clinically indicated. No treatment was given for DSAs in the absence of biopsy-proven rejection. Results. Twenty (19%) patients had dnDSA first detected on a screening test, and 13 (13%) patients had dnDSA first detected on a for-cause test. Mean follow-up time posttransplant was 4.4 years. Screening-detected dnDSA was associated with an increased risk of rejection within 3 years, microvascular inflammation, and C4d staining on a 2-year protocol biopsy. In a Cox proportional hazards regression, screening-detected dnDSA was not associated with time to 30% decline in estimated glomerular filtration rate (adjusted hazard ratio, 0.88; 95% confidence interval [CI], 0.30-2.00; P = 0.598) or graft loss. dnDSA first detected on for-cause testing was associated with a 2.8 times increased risk of decline in graft function (95% CI, 1.08-7.27; P = 0.034) and a 7.34 times increased risk of graft loss (95% CI, 1.37-39.23 P = 0.020) compared with those who did not develop dnDSA. Conclusions. The clinical setting in which dnDSA is first detected impacts the association between dnDSA and graft function. Further research is needed to clarify the role of dnDSA screening in pediatric kidney transplantation.
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Background. The development of de novo donor-specific antibodies (dnDSA) has been associated with rejection and graft loss in kidney transplantation, and DSA screening is now recommended in all kidney transplant recipients. However, the clinical significance of dnDSA detected by screening patients with a stable creatinine remains unclear. Methods. One hundred three patients younger than 18 years receiving a first, kidney alone transplant between December 1, 2007, and December 31, 2013 , underwent DSA screening every 3 months for 2 years posttransplant, with additional testing as clinically indicated. No treatment was given for DSAs in the absence of biopsy-proven rejection. Results. Twenty (19%) patients had dnDSA first detected on a screening test, and 13 (13%) patients had dnDSA first detected on a for-cause test. Mean follow-up time posttransplant was 4.4 years. Screening-detected dnDSA was associated with an increased risk of rejection within 3 years, microvascular inflammation, and C4d staining on a 2-year protocol biopsy. In a Cox proportional hazards regression, screening-detected dnDSA was not associated with time to 30% decline in estimated glomerular filtration rate (adjusted hazard ratio, 0.88; 95% confidence interval [CI] , 0.30-2.00; P = 0.598) or graft loss. dnDSA first detected on for-cause testing was associated with a 2.8 times increased risk of decline in graft function (95% CI, 1.08-7.27; P = 0.034) and a 7.34 times increased risk of graft loss (95% CI, 1.37-39.23 P = 0.020) compared with those who did not develop dnDSA. Conclusions. The clinical setting in which dnDSA is first detected impacts the association between dnDSA and graft function. Further research is needed to clarify the role of dnDSA screening in pediatric kidney transplantation. I n 2014, 17814 individuals in the United States received a kidney transplant, 712 of them were children. 1 Over the past 30 years, there has been substantial increase in kidney allograft survival, but most of these have been due to improvements in short-term rather than long-term survival. 2 Chronic allograft nephropathy (including interstitial fibrosis with tubular atrophy [IFTA] and transplant glomerulitis) remains the leading cause of graft loss, 3 and HLA antibodies are thought to play a key role in its development. 4 Donor-specific antibodies (DSAs) are antibodies developed by the transplant recipient against HLA antigens present on the donor kidney. Numerous studies have linked the development of de novo DSAs (dnDSA) after kidney transplantation to poor graft outcomes in both adults and children. 1, [5] [6] [7] [8] [9] [10] [11] [12] This has resulted in recommendations that patients undergo routine screening for the development of dnDSA posttransplant. 13 However, many of these original studies combined screening with testing done in the setting of graft dysfunction 1, 6, 10, 14, 15 or screened stored serum without regard to the patient's clinical status. [7] [8] [9] 12 This raises concern that the association between dnDSA and graft outcome seen in prior studies may not be representative of a population with stable kidney function undergoing screening.
Multiple studies have shown that a large subset (34-48%) of patients who develop dnDSAs develop neither rejection nor have a decline in graft function. 1, 7, 9, 14, 15 In a subgroup analysis of their study of 244 adult patients, Cooper et al 14 reported that the 2-year graft survival among those with dnDSA detected on a protocol test was 93% compared with 97.8% among those without dnDSA, a difference that was not statistically significant. In this study, we aim to examine whether or not patients younger than 18 years at the time of transplant with de novo DSAs first detected in the setting of stable kidney graft function have worse outcomes than those with no dnDSA.
MATERIALS AND METHODS
We performed a retrospective cohort study of all pediatric patients receiving a kidney transplant at Seattle Children's Hospital between December 1, 2007, and December 31, 2013 . Inclusion criteria were younger than 18 years at the time of transplant, receipt of a primary, kidney-alone transplant, and at least 2 years of DSA monitoring. Exclusion criteria included prior kidney transplant, previous or concurrent other solid organ transplant, and previous hematopoietic stem cell transplant. All patients had a negative crossmatch and no DSA before transplant.
Induction immunosuppression was with methylprednisolone and either thymoglobulin or an IL-2 receptor antagonist (basiliximab or daclizumab). Maintenance immunosuppression was primarily with tacrolimus and mycophenolate mofetil. Maintenance tacrolimus level goals were 10 to 12 ng/dL from 3 to 59 days posttransplant, 7 to 10 ng/mL from 60 to 84 days posttransplant, 5 to 7 ng/mL from 85 to 365 days posttransplant, and 3 to 5 ng/mL from longer than 365 days posttransplant. Mycophenolate mofetil was dosed at 600 mg/m 2 per dose (maximum 1000 mg/dose) IV every 12 hours, beginning in the operating room, and transitioned to 450 mg/m 2 per dose (maximum, 750 mg/dose), orally every 12 hours once the tacrolimus level was at goal. Mycophenolate mofetil dosing was decreased to 300 mg/m 2 per dose (maximum, 500 mg/dose) orally every 12 hours beginning 14 days posttransplant. Maintenance steroids were reserved for patients on a sirolimus protocol or who required steroids for other underlying diseases. All patients received Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole or pentamidine for 12 months posttransplant, antifungal prophylaxis with nystatin or clotrimazole for 1 month posttransplant, and cytomegalovirus (CMV) antiviral prophylaxis with valganciclovir for 6 months posttransplant.
As a surrogate for medication adherence, we calculated the coefficient of variation (CV), equal to the standard deviation divided by the mean, multiplied by 100, of tacrolimus trough levels. 16 Coefficient of variations were calculated separately for the periods of 85 to 365 days posttransplant and 366 to 730 days posttransplant; a weighted average of the 2 coefficients was then calculated for each patient. Tacrolimus whole-blood concentration was measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) using Waters Quattro micro or Waters TQ-S micro with a variability of 4.1% to 6.5%. Coefficient of variation was not calculated for patients on sirolimus.
Patients underwent surveillance kidney biopsies between 3 and 6 months posttransplant, between 6 and 12 months posttransplant, and at approximately 24 months posttransplant. All rejection episodes were biopsy-proven; no rejection treatment was given in the absence of a Banff criteria diagnosis of rejection. Acute cellular rejection episodes were treated with 3 days of methylprednisolone (30 mg/kg per day IV, maximum 1000 mg/d) followed by a prednisone taper. Antibody-mediated rejection was treated with plasmapheresis daily for 3 days followed by intravenous immunoglobulin and rituximab.
Since January 2008, pediatric kidney transplant patients at Seattle Children's Hospital have undergone DSA screening every 3 months as part of routine clinical care. BloodWorks Northwest (Seattle, WA), a United Network for Organ Sharingaccredited laboratory that specializes in testing for organ transplantation, performed all DSA tests and provided the results. All DSA results within the first 2 years posttransplant were included in analysis. DSA screening was performed by Luminex technology (either the Luminex 200 or FLEXMAP 3D platform) using single-antigen beads (OneLambda, CA). At our institution, a median fluorescence intensity (MFI) less than 2500 is considered "weak," an MFI of 2500 to less than 8000 is considered "moderate," and an MFI greater than 8000 is considered "strong." All other data were collected from the electronic medical record.
Patients were divided into 3 categories for analysis: patients who developed dnDSA first detected on a screening test, patients who developed dnDSA first detected on a forcause test, and those who never developed a dnDSA. For all patients with a positive DSA test, the creatinine at the time of the positive test was compared to a baseline in a window 3 to 6 months prior, defined as the lowest creatinine measured on 2 occasions at least 1 week apart. The screeningdetected group was defined as those whose creatinine at the time of first positive dnDSA test was no more than 0.1 mg/dL higher than the baseline in a window 3 to 6 months prior. The for-cause group included those patients whose creatinine at the time of the first positive dnDSA test was at least 0.2 mg/dL higher than it had been in the previous 3 to 6 months. Once patients were grouped based on their first positive DSA test, group assignment did not change, regardless of future changes in DSA results or creatinine. No threshold was used to define a positive DSA result; the lowest reported MFI in this study was 300. No immunosuppression was adjusted, nor was treatment was given, for dnDSA in the absence of biopsy-proven acute rejection.
Estimated glomerular filtration rate (eGFR) was calculated using the Modified Schwartz equation 17 for patients younger than 18 years and the CKD-EPI equation 18 once patients were 18 years or older. Baseline eGFR posttransplant was calculated using the lowest serum creatinine obtained on 2 occasions at least 1 week apart within the first 60 days after transplant.
The primary outcome of this study was a 30% decline in eGFR, defined as the number of days after transplant when the eGFR fell below 30% of the posttransplant baseline and did not recover within 30 days. A 30% decline in eGFR has been endorsed as a surrogate endpoint for end-stage renal disease that can allow studies to be conducted over shorter time periods and with a smaller number of patients. 19, 20 Secondary outcomes included graft loss, eGFR at 3 years posttransplant, the number of biopsy-proven rejection episodes within 3 years after transplant, and the incidence of microvascular inflammation, C4d staining, and IFTA on the 2-year protocol biopsy. All biopsies for this study were examined by our renal pathologist using Banff 2007 criteria. Microvascular inflammation was defined as a glomerulitis or peritubular capillaritis score greater than 1. C4d staining was assessed on formalin-fixed paraffin-embedded sections stained by immunohistochemistry. Cases with staining in greater than 10% of tissue were considered positive.
Descriptive statistics used means and standard deviations for normally distributed data and medians and interquartile ranges for skewed data. Using Cox proportional hazards regression, transplant recipients with and without dnDSA were compared for the time to a 30% decline in eGFR and time to graft loss. We used linear regression to examine the relation between developing dnDSA and eGFR at 3 years posttransplant and logistic regression to examine the relative incidence of IFTA. The hazard of rejection was compared using a Cox proportional hazards model with dnDSA as a timevarying covariate and allowing for multiple rejection episodes per transplant recipient. Once recipients developed dnDSA, they were considered to be DSA-positive for the remainder of the follow-up time, even if DSA later resolved. In cases where patients had multiple rejection episodes, time to rejection was calculated from the previous episode. The previous number of episodes was adjusted for in the model by stratification, and robust standard error estimates were used to account for correlation caused by multiple episodes in the same patient. All outcomes were adjusted for confounding by age, type of transplant donor, delayed graft function, cold ischemia time, and baseline eGFR posttransplant, determined on an a priori basis.
Two sensitivity analyses for the primary outcome were performed, 1 using varying MFI thresholds for defining a positive DSA test and 1 dichotomizing the highest MFI on the first positive DSA test into weak (MFI, <2500) or moderate/strong (MFI, ≥ 2500). Dichotomized MFI groups were also used to look at pathology outcomes using Fisher exact testing. Analysis was conducted using STATA 12. This study was approved by the Seattle Children's Hospital Institutional Review Board, study 13646.
RESULTS

Study Population
One hundred thirty-eight kidney transplants were performed at Seattle Children's Hospital between December 1, 2007, and December 31, 2013 . Among the transplant recipients, 15 were excluded because they were older than 18 years, 12 had a previous solid organ transplant, 1 underwent a multiorgan transplant, and 7 had less than 2 years of DSA screening due to either graft failure prior to 1 year (n = 2) or transfer of care to another institution (n = 5) (Figure 1 ). In total, 103 patients were included in the study. Eighty-one percent of the patients had 6 or more DSA tests during the first 2 years after transplant. Mean follow-up time was 4.4 years posttransplant.
Thirty-three (32%) patients developed dnDSA within 2 years posttransplant; 20 (19%) patients had dnDSA first detected by screening, whereas 13 (13%) patients were detected on for-cause testing. Patients with screening-detected dnDSA tended to be younger than those without dnDSA, whereas those with for-cause detected dnDSA tended to be older. Those with screening-detected dnDSA were more likely to have had delayed graft function, a longer cold ischemia time, and Epstein-Barr virus or CMV mismatch compared with those without dnDSA. Patients with for-cause detected dnDSA were more likely to have received a deceased donor transplant, have a longer cold ischemia time, and undergo induction with an IL-2 inhibitor. Patients with dnDSA detected in any setting had a median of 4 renal biopsies, more than 1 was generally seen among those without dnDSA. Patients in the 3 study groups were otherwise similar (Table 1) .
dnDSA Characteristics
Patients with screening-detected dnDSA tended to develop dnDSA earlier, and the dnDSA persisted longer than those with dnDSA detected on a for-cause test. Those with dnDSA on a for-cause test were more likely to have antibodies against class I HLA (15%) or both class I and class II HLA (31%) compared with those with screening dnDSA (10% and 10%, respectively). Conversely, those with screening-detected dnDSA were more likely to have isolated class II HLA antibodies (80%). The 2 groups had similar peak MFIs and rates of C1q positivity. Approximately 30% of detected dnDSAs resolved before the end of 2 years of monitoring in both groups (Table 2) . There was no difference in our surrogate marker for adherence, mean CV of tacrolimus trough level, between those with screening-detected dnDSA and those with dnDSA detected on for-cause testing (P = 0.924, Table 2 ).
Outcomes of Patients With dnDSA
In a Cox proportional hazards regression controlling for age at transplant, type of transplant donor, incidence of delayed graft function, cold ischemia time, and baseline posttransplant eGFR, there was no significant difference in the occurrence of a 30% decline in eGFR between those with screening-detected dnDSA and those who never developed DSA (adjusted hazard ratio [aHR], 0.88; 95% CI, 0.30-2.00; P = 0.598) (Table 3A; Figure 2A ). There was an increased HR for graft loss, but the result was not statistically significant (aHR, 1.75; 95% CI, 0.28-10.73; P = 0.546). There was also no difference for eGFR at 3 years posttransplant (difference, −1.08 mL/min per 1.73 m 2 ; P = 0.616). Patients with dnDSA detected on for-cause testing did have an increased risk of decline in graft function (aHR, 2.80; 95% CI, 1.08-7.27; P = 0.034), an increased risk of graft loss (aHR, 7.34; 95% CI, 1.37-39.23; P = 0.020), and a lower ; P = 0.054) compared with those without dnDSA after adjustment for age at transplant, type of transplant donor, incidence of delayed graft function, cold ischemia time, and baseline eGFR (Table 3A, Figure 2B ).
The development of dnDSA was associated with an increased risk of an episode of any type of rejection within 3 years posttransplant regardless of circumstances of dnDSA detection. The incidence of rejection in patients without dnDSA was 15 per 100 person-years, compared to 36 per 100 person-years in those with screening-detected dnDSA and 71 per 100 person-years in those with dnDSA done for-cause (Table 3A) . In a Cox proportional hazards analysis with dnDSA status as a time-varying exposure, allowing for multiple rejection episodes per patient, and adjusted for age at transplant, type of transplant donor, incidence of delayed graft function, cold ischemia time, and baseline posttransplant eGFR, patients with screening-detected dnDSA, and those with dnDSA on for-cause testing had a similar increased hazard for subsequent rejection episodes (dnDSA on screening: aHR, 2.41; 95% CI, 1.27-4.54; P = 0.007; dnDSA on forcause testing: aHR, 2.43; 95% CI, 1.00-5.90; P = 0.050).
Patients who developed dnDSA were more likely to have microvascular inflammation and C4d staining on their protocol biopsy 2 years after transplant compared with those without dnDSA (Table 3B ). The incidence of microvascular inflammation was higher among those with dnDSA on for-cause testing (42%) compared with those with screening-detected dnDSA (24%), whereas the incidence of C4d staining was similar between the 2 groups. There was no association between dnDSA and IFTA in this study.
In a sensitivity analysis that used different MFI thresholds to define a positive DSA test, there was no change in time to a 30% decline in eGFR when using MFI thresholds of 1000, 1500, 2500, or 8000 (Table 4) . In a separate analysis, we dichotomized patients with dnDSA by their highest MFI on their initial positive DSA test into <2500 and ≥ 2500. In this analysis, we found similar results for the primary outcome of a 30% decline in eGFR. We also found a similar incidence of antibodymediated rejection, graft failure, microvascular inflammation, c4d positivity, and IFTA between the 2 groups (Table 5) .
DISCUSSION
In this study, we show that clinically stable patients who are first diagnosed with dnDSAs on a screening test have an increased risk of acute rejection, microvascular inflammation, and C4d deposition compared with those patients who never develop dnDSA. However, we could not show an increased risk of decline in graft function or graft loss. Consistent with previous studies, we show that patients who develop dnDSA detected on for-cause testing do have an increased risk for decline in graft function and graft loss. To the best of our knowledge, this is the largest study to Results are adjusted for age at transplant, type of transplant donor, incidence of delayed graft function, cold ischemia time, and baseline eGFR.
FIGURE 2. Kaplan-Meier survival curves for (A) time to a 30% decline in eGFR and (B) time to graft loss among pediatric kidney transplant patients, subdivided by presence of dnDSA and clinical setting of dnDSA detection.
examine the outcomes of screening dnDSA in pediatric kidney transplant patients. Much of the previous literature on dnDSA and graft outcomes has combined data on screening in clinically asymptomatic patients with data from patients with graft dysfunction. 1, 5, 10, 14 Although this was logical given the goals of those studies, it may not be appropriate to apply those results to a clinically stable population undergoing DSA screening. Our data and the data from Wiebe et al 15 and Cooper et al 14 suggest that patients who are clinically stable and those with graft dysfunction represent distinct groups with different risks of poor graft outcome. This means that the results of those prior studies could overstate the risk of dnDSA in clinically stable patients while understating the risk in those with graft dysfunction. This is perhaps best illustrated in the study by Cooper et al, who reported an overall HR for 2 year graft loss of 7.7 among those with dnDSA. However, our review of their reported outcomes shows that, when their patient population was divided into those with dnDSA on protocol testing vs nonprotocol testing, the relative risk of 2-year graft loss was 3.2 for the protocol group and 28.6 for the nonprotocol group-a ninefold difference. 14 There is already evidence that not all dnDSA have equal propensity to damage the kidney. Studies have shown an increased risk of graft loss among patients with anti-HLA class II antibodies, 21 anti-DQ antibodies, 22 and antibodies with a higher MFI.
8 Donor-specific antibodies are thought to damage the renal microvasculature via complement fixation, and several research groups have found an increased risk of graft loss caused by DSAs that bind complement proteins C1q 23, 24 or C3d. 25 However, the strong association between C1q or C3d binding ability and DSA MFI has raised concerns about the validity of these assays. 26, 27 It is possible that the types of dnDSA that develop in patients who are otherwise clinically stable may differ from the dnDSA in patients with graft dysfunction, which could explain the difference in outcome seen in our study. A higher percentage of patients with dnDSA detected on for-cause testing had both class I and class II antibodies; however, this study was not designed or powered to detect differences in antibody characteristics. Further research with larger patient populations is needed to better clarify the types of antibodies that are most harmful to the renal allograft.
Both acute rejection 2 and microvascular inflammation [28] [29] [30] have been associated with decreased graft survival, whereas the impact of C4d staining on graft survival is more questionable. 28, [30] [31] [32] However, in our study, screening-detected dnDSA was not associated with a faster decline in graft function despite being associated with both acute rejection and microvascular inflammation. One explanation for this may be that acute rejection and microvascular inflammation represent the first steps leading to a later decline in graft function that was not captured in our follow-up. However, those transplant recipients with dnDSA detected on for-cause testing were shown to have a higher rate of decline in graft function and graft failure within the study follow-up time, despite generally developing dnDSA later (median 543 days) than those patients with screeningdetected dnDSA (median, 332 days). Alternatively, the association between acute rejection and graft function may be more nuanced than previously thought. In their original study of the association between acute rejection and graft loss, Meier Kriesche et al 2 noted that graft survival among patients whose renal function returned to baseline after a rejection episode was no different than patients without rejection episodes. It is possible that the biopsy findings associated with screeningdetected dnDSA represent a different, more indolent, process than that in patients with dnDSA detected on for-cause testing.
The study used a rich clinical data source that included DSA screening results and biopsy data on patients during times of both clinical stability and graft dysfunction. This allows fuller assessment of both dnDSA incidence and pathologic changes throughout the posttransplant course. It also took advantage of a large pediatric cohort managed at a single institution under a single standardized set of transplant protocols, decreasing the variation in outcome that could be introduced by variations in immunosuppression management. The use of survival techniques allowed us to take full advantage of the long follow-up times available on many of the study's patients.
The chief limitation of this study is that the follow-up period may not have been long enough to fully monitor the association between the presence of dnDSA and long-term outcome. Antibody-mediated damage is hypothesized to be an indolent process. 15 Terasaki 33 published data showing a mean time from detection of dnDSA to graft failure of approximately 2.9 years. 33 Although the mean posttransplant follow-up time in our study was 4.5 years, 25% of patients in the dnDSA-stable creatinine group had less than 2 years of follow-up after their first positive DSA test. However, our primary outcome was a 30% decline in renal function, not graft loss. A 30% decline in eGFR is a surrogate endpoint that allows for shorter trial durations while maintaining a chance of type I error of less than 5%. 20 Therefore, the shorter duration of follow-up in our study may be somewhat mitigated. A second limitation is that we found an increased number of biopsies in the group with screening-detected dnDSA, suggesting that the detection of dnDSA, while not directly prompting treatment, may have led to increased surveillance and, therefore, detection of rejection.
In conclusion, we demonstrated that the clinical setting in which dnDSA is first detected impacts the association between dnDSA and graft function. Screening-detected dnDSA was associated with an increased risk of rejection episodes, microvascular inflammation, and C4d deposition but not associated with a decline in graft function, suggesting that there may be ongoing subclinical renal damage. Further study is needed to establish the role of dnDSA screening in the pediatric kidney transplant population to clarify the types of antibodies that are most associated with harm to the graft and to guide interventions. IFTA II or III n (%) n (%) n (%) n (%) Screening dnDSA <2500 8 (47%) 2 (25%) 3 (37%) 3 (38%) ≥2500 9 (53%) 2 (22%) 3 (33%) 3 (33%) P = 1.00 P = 1.00 P = 1.00 For-cause dnDSA <2500 8 (66%) 4 (50%) 2 (25%) 0 (0%) ≥2500 4 (33%) 1 (25%) 2 (50%) 1 (25%) P = 0.576 P = 0.547 P = 0.333 a Microvascular inflammation defined as a glomerulitis or peritubular capillaritis score > 0; p-y: person-years. b Each episode of antibody mediated rejection occurred in 1 individual patient. Primary outcome of 30% decline in eGFR evaluated by Cox proportional hazards regression adjusted for age at transplant, type of transplant donor, delayed graft function, cold ischemia time, and baseline eGFR. All other outcomes evaluated using Fisher Exact testing without adjustment.
